- Home
- LOMA vs TRVI Comparison
LOMA vs TRVI Comparison
Compare LOMA & TRVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LOMA | TRVI |
|---|---|---|
| Founded | 1926 | 2011 |
| Country | Argentina | United States |
| Employees | N/A | N/A |
| Industry | Building Materials | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.5B |
| IPO Year | 2017 | 2019 |
Fundamental Metrics
Financial Performance| Metric | LOMA | TRVI |
|---|---|---|
| Price | $10.10 | $12.95 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 12 |
| Target Price | $15.00 | ★ $20.38 |
| AVG Volume (30 Days) | 299.2K | ★ 1.2M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $22.92 | N/A |
| Revenue Next Year | $25.84 | N/A |
| P/E Ratio | $187.97 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $7.04 | $4.24 |
| 52 Week High | $14.17 | $14.39 |
Technical Indicators
Market Signals| Indicator | LOMA | TRVI |
|---|---|---|
| Relative Strength Index (RSI) | 33.37 | 67.91 |
| Support Level | $7.26 | $10.04 |
| Resistance Level | $12.33 | $14.39 |
| Average True Range (ATR) | 0.53 | 0.69 |
| MACD | -0.11 | 0.25 |
| Stochastic Oscillator | 12.93 | 84.82 |
Price Performance
Historical ComparisonAbout LOMA Loma Negra Compania Industrial Argentina Sociedad Anonima ADS
Loma Negra Cia Industria Argentina SA is a cement producer in Argentina. The company operates in five segments: Cement, masonry cement, and lime; Concrete; Rail services; Aggregates; and Others. The majority of its revenue derives from Cement, masonry cement, and lime segments.
About TRVI Trevi Therapeutics Inc.
Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, and other chronic cough indications, and for the treatment of prurigo nodularis. Haduvio is an oral extended-release formulation of nalbuphine.